1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,264 | 0,304 | 07:45 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | JW THERAP-B (02126): GRANT OF SHARE OPTIONS AND GRANT OF RESTRICTED SHARE UNITS | 1 | HKEx | ||
| 29.12.25 | JW THERAP-B (02126): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| 22.12.25 | JW THERAP-B (02126): CONTINUING CONNECTED TRANSACTION IN RELATION TO EXTENSION OF TERM OF VECTOR SUPPLY AGREEMENT | - | HKEx | ||
| 12.12.25 | JW THERAP-B (02126): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| 12.12.25 | JW THERAP-B (02126): (1) APPOINTMENT OF CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR; (2) APPOINTMENT OF CHAIRMAN OF THE BOARD; (3) RESIGNATION OF CHIEF ... | 1 | HKEx | ||
| JW THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.12.25 | JW THERAP-B (02126): VOLUNTARY ANNOUNCEMENT - RESEARCH AND DEVELOPMENT UPDATE - PRESENTATION OF JWCAR201 IIT STUDY DATA AT THE 67TH AMERICAN SOCIETY OF ... | - | HKEx | ||
| 28.11.25 | Imugene And JW Therapeutics Collaborate On Solid Tumor Therapy | - | RTTNews | ||
| 30.10.25 | JW THERAP-B (02126): MAJOR TRANSACTION IN RELATION TO AMENDMENT NO. 1 TO THE COLLABORATION AGREEMENT | - | HKEx | ||
| 21.10.25 | JW THERAP-B (02126): VOLUNTARY ANNOUNCEMENT - RESEARCH AND DEVELOPMENT UPDATE - DATA SUBMITTED FROM PHASE I STUDY OF RELMA-CEL IN CHINESE ADULT PATIENTS ... | 1 | HKEx | ||
| 10.10.25 | China Reviews JW Therapeutics' Plan to Use Own Lentiviral Vector to Cut Cost of CAR-T Cancer Drug | 1 | Yicai Global | ||
| 09.10.25 | JW THERAP-B (02126): VOLUNTARY ANNOUNCEMENT - RESEARCH AND DEVELOPMENT UPDATE - NATIONAL MEDICAL PRODUCTS ADMINISTRATION OFFICIALLY ACCEPTED THE POST-MARKETING ... | - | HKEx | ||
| 30.09.25 | JW THERAP-B (02126): DELAY IN DESPATCH OF CIRCULAR | - | HKEx | ||
| 25.09.25 | JW THERAP-B (02126): 2025 INTERIM REPORT | - | HKEx | ||
| 16.09.25 | JW THERAP-B (02126): GRANT OF SHARE OPTIONS | 2 | HKEx | ||
| 27.08.25 | JW THERAP-B (02126): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND CHANGE IN USE OF NET PROCEEDS FROM LISTING | - | HKEx | ||
| 15.08.25 | JW THERAP-B (02126): NOTICE OF BOARD MEETING | 1 | HKEx |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 46,250 | 0,00 % | Schlägt Thermo Fisher zu?: Qiagen: Übernahmegerüchte schicken die Aktie auf Kursachterbahn | © Foto: Rafael Henrique - picture allianceÜbernahmegerüchte um den Diagnostikspezialisten Qiagen sorgten am Dienstag für einen rekordverdächtigen Kursanstieg. Am Mittwoch kommt die Aktie wieder etwas... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 93,79 | +3,04 % | Guggenheim raises Structure Therapeutics stock price target to $140 on obesity drug confidence | ||
| CG ONCOLOGY | 57,13 | +4,46 % | What Analysts Are Saying About CG Oncology Stock | ||
| COGENT BIOSCIENCES | 39,900 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,64 | +0,23 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ALUMIS | 26,680 | 0,00 % | Chardan Capital initiates coverage on Alumis stock with Buy rating | ||
| PRAXIS PRECISION MEDICINES | 312,60 | -3,54 % | Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus | ||
| KYMERA THERAPEUTICS | 70,74 | 0,00 % | Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (25 Ratings) | ||
| BEAM THERAPEUTICS | 31,120 | 0,00 % | Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway | ||
| KINIKSA PHARMACEUTICALS | 41,830 | +1,95 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Provides Corporate Update | - ARCALYST- (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth -- ARCALYST 2026 net product revenue expected to be $900 - $920 million --... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,850 | 0,00 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| ERASCA | 10,050 | 0,00 % | Erasca, Inc.: Erasca Announces Proposed Public Offering of $150 Million of Common Stock | SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| VERA THERAPEUTICS | 45,770 | +2,10 % | Cantor Fitzgerald reiterates Overweight rating on Vera Therapeutics stock | ||
| IMMUNOME | 24,870 | +4,15 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| TANGO THERAPEUTICS | 12,500 | -0,08 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor | Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately... ► Artikel lesen |
JW CAYMAN THERAPEUTICS CO LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,316 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JW CAYMAN THERAPEUTICS CO LTD finden Sie auf Wallstreet Online.